Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Cancer Chemotherapy and Pharmacology|August 19, 2011
Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal diseaseJuliette Thariat, Marie-Christine Etienne-Grimaldi, Vincent Launay-Vacher, et al.
Bone Marrow Transplantation|February 10, 2021
Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemiaCécile Pautas, Emmanuel Raffoux, Juliette Lambert, et al.
Leukemia & Lymphoma|January 8, 2015
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphomaNicolas Martin, Delphine Borchiellini, Diane Coso, et al.
American Journal of Hematology|June 13, 2013
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with AzacitidineThomas Cluzeau, Nicolas Mounier, Jean-Michel Karsenti, et al.
International Journal of Radiation Oncology, Biology, Physics|May 31, 2023
Single-Masked Randomized Phase 2 Study Assessing 2 Forms of Hypofractionated Proton Therapy in Patients With Large Choroidal MelanomasJuliette Thariat, Thibaud Mathis, Tanguy Pace-Loscos, et al.
International Journal of Molecular Sciences|July 14, 2023
Assessment of Different Circulating Tumor Cell Platforms for Uveal Melanoma: Potential Impact for Future Routine Clinical PracticeArnaud Martel, Baharia Mograbi, Barnabe Romeo, et al.
European Journal of Haematology|January 29, 2020
Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatmentAnne Calleja, Seongseok Yun, Chimène Moreilhon, et al.
Melanoma Management|January 27, 2025
Early palliative care in metastatic uveal melanoma (early together): protocol of a prospective randomized Phase III trialSophie Piperno-Neumann, Leanne de Koning, Timothée Marchal, et al.
Cancers|May 16, 2023
Need for a Dedicated Ophthalmic Malignancy Clinico-Biological Biobank: The Nice Ocular MAlignancy (NOMA) BiobankArnaud Martel, Lauris Gastaud, Christelle Bonnetaud, et al.
Bulletin Du Cancer|September 16, 2018
[Management of uveal melanomas, guidelines for oncologists]Thibaud Mathis, Nathalie Cassoux, Magali Tardy, et al.
Pageof 5